论文部分内容阅读
目的探讨配对盒基因9(Pax-9)在肺腺癌患者血清中的表达及临床意义。方法采用酶联免疫吸附法(ELISA)测定30例肺腺癌患者血清中Pax-9的浓度,同时检测48例良性肺病变(慢性阻塞性肺疾病、肺炎)患者和32例健康者血清中Pax-9的浓度以作为对照。并分析其表达与患者临床病理特征及患者预后的关系。结果肺腺癌患者血清中Pax-9的浓度([147.9±91.7)ng/mL]明显高于肺良性病变患者血清中Pax-9的浓度([95.2±42.4)ng/mL]和健康对照组血清中的浓度([103.6±56.4)ng/mL],差异有统计学意义(P<0.05)。Pax-9的表达水平与患者性别、年龄、吸烟史及淋巴转移等临床病理特征无关(P>0.05),与肿瘤TNM分期显著相关,血清中Pax-9的浓度随TNM分期而升高,Ⅲ～Ⅳ期([173.0±94.7)ng/mL]明显高于Ⅰ～Ⅱ期([97.6±63.2)ng/mL](P<0.05)。Kaplan-Meier分析显示,Pax-9高表达组患者的中位生存时间为22.5个月,低于低表达组患者的中位生存时间24.0个月,差异有统计学意义(P<0.05)。COX回归分析显示,TMN分期和Pax-9表达对肺腺癌患者预后具有显著意义(P<0.05)。结论 Pax-9在肺癌的发生发展中起一定作用,检测其血清含量对肺癌的诊断具有一定的临床意义,其过高表达有可能作为腺癌预后不良的评估指标。
Objective To investigate the expression and clinical significance of pax-9 gene in serum of patients with lung adenocarcinoma. Methods Serum concentrations of Pax-9 in 30 patients with lung adenocarcinoma were determined by enzyme-linked immunosorbent assay (ELISA). Pax-9 was also detected in 48 patients with benign lung disease (COPD, pneumonia) and 32 healthy controls -9 as a control. And analyze the relationship between its expression and the clinicopathological features and prognosis of patients. Results The serum concentration of Pax-9 ([147.9 ± 91.7 ng / mL]) was significantly higher in patients with lung adenocarcinoma than that in healthy controls ([95.2 ± 42.4] ng / mL] Serum concentration ([103.6 ± 56.4] ng / mL], the difference was statistically significant (P <0.05). The expression level of Pax-9 was not related to clinicopathological features such as sex, age, smoking history and lymphatic metastasis (P> 0.05), but significantly correlated with TNM staging of tumor. The Pax-9 concentration in serum increased with TNM staging. ~ Ⅳ ([173.0 ± 94.7] ng / mL] was significantly higher than that of stage Ⅰ ~ Ⅱ ([97.6 ± 63.2] ng / mL] (P <0.05). Kaplan-Meier analysis showed that the median survival time of Pax-9 high expression group was 22.5 months, which was lower than that of the low expression group 24.0 months (P <0.05). COX regression analysis showed that TMN staging and Pax-9 expression had a significant effect on the prognosis of patients with lung adenocarcinoma (P <0.05). Conclusion Pax-9 plays a role in the development and progression of lung cancer. Detecting the serum level of Pax-9 has some clinical significance in the diagnosis of lung cancer. The overexpression of Pax-9 may be used as an index to evaluate the prognosis of lung cancer.